Study S000443

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04137328
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 60
Start: 2019-11-30
Primary completion: 2022-11-30
Lead sponsor: Fudan University
Conditions: Diabetic Neuropathic Pain
Interventions: DRUG:Liraglutide; DRUG:insulin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Numerical pain scale (NRS) [3 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017061	Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses. Lee CH, Molecular neurobiology	2018	Preclinical	PMID 28456941 DOI	registry reference BACKGROUND:28456941
R0016230	The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Vinué Á, Diabetologia	2017	Preclinical	PMID 28608285 DOI	registry reference BACKGROUND:28608285
R0021815	Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Bruen R, Cardiovascular diabetology	2017	Preclinical	PMID 29110715 DOI	registry reference BACKGROUND:29110715
R0024462	Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals. Hirano T, Journal of diabetes investigation	2016	Preclinical	PMID 27186361 DOI	registry reference BACKGROUND:27186361